NT
NTRA
| Investor | Firm | Position | Weight | As of |
|---|---|---|---|---|
| Stanley Druckenmiller | Duquesne Family Office | $865M | 16.6% | 2026-06-30 |
| Philippe Laffont | Coatue Management | $680M | 1.4% | 2026-06-30 |
| Azzad Asset Management | Azzad Asset Management | $3M | 0.2% | 2026-06-30 |
| Ray Dalio | Bridgewater Associates | $2M | 0.0% | 2026-06-30 |
From the most recent 13F on file. A 13F reports long US equity positions quarterly and in arrears — it is what a manager held on the report date, not what they hold today.
Methodology breakdown computing — it will appear here on its own.
Natera Inc (NTRA) is currently considered halal (Sharia-compliant), per our secondary compliance provider (last assessed 2026-08-12). See the full ratio breakdown and business-activity screen below for the reasoning.
🕌 In-house Compliance Research
Computing the full ratio and business-activity breakdown for NTRA — this runs off the critical path so the page paints first. It will appear here on its own.
Pinch or scroll to zoom · drag to pan — both axes move · double-click to reset
Classic floor-trader pivots from the last completed daily bar. Highlighted pills are the levels bracketing the current price.
Price Forecast
The range is measured volatility (ATR over the horizon), not a target — a wider band means a more volatile asset, not a stronger view. The direction is the indicator tally above. Every forecast is recorded when made and scored against the real price when it comes due, including the wrong ones. Not a recommendation, and not a fatwa.
Technical Summary
Every indicator, and what it reads
| Indicator | Value | Signal |
|---|---|---|
| RSI (14) | 58.40 | NEUTRAL |
| Stochastic %K (14) | 37.31 | NEUTRAL |
| CCI (20) | 15.47 | NEUTRAL |
| Williams %R (14) | -62.69 | NEUTRAL |
| MACD (12,26,9) | -2.43 | SELL |
| ROC (10) | -3.64 | SELL |
| Momentum (10) | -12.31 | SELL |
| EMA (10) | 326.39 | SELL |
| SMA (10) | 326.93 | SELL |
| EMA (20) | 320.60 | BUY |
| SMA (20) | 325.03 | BUY |
| EMA (30) | 312.57 | BUY |
| SMA (30) | 313.09 | BUY |
| EMA (50) | 297.07 | BUY |
| SMA (50) | 295.77 | BUY |
| EMA (100) | 270.06 | BUY |
| SMA (100) | 255.48 | BUY |
| EMA (200) | 244.90 | BUY |
| SMA (200) | 237.26 | BUY |
Standard indicator thresholds (RSI 30/70, Stochastic 20/80, CCI ±100, Williams %R −80/−20, MACD histogram sign, price vs. average) computed on daily bars. A summary of what common indicators say — not a recommendation, and not this site's own trading verdict.
About Natera Inc
Healthcare · Diagnostics & Research
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic profiling test; and Empower, a hereditary cancer screening test. The company also provides Panorama, a non-invasive prenatal test; Horizon, a carrier screening test; Fetal Focus, a single-gene NIPT, or sgNIPT, that screens for 21 single-gene inherited conditions; and Vistara, a single-gene NIPT, which screens for 25 single-gene conditions. In addition, it offers Anora, which tests and analyzes miscarriage tissue from women who have experienced one or more pregnancy losses; Empower, a hereditary cancer screening test; Prospera, a test to assess active rejection in patients who have undergone solid organ transplantation; Renasight, a kidney gene panel test; and Constellation software, a cloud-based distribution model. Further, the company provides NateraCore, a platform to support the patient and provider experience; phlebotomy services; and EMR integration services. The company serves independent laboratories, national and regional reference laboratories, medical centers and physician practices for its screening tests, research laboratories, and pharmaceutical companies through its direct sales force and laboratory distribution partners, as well as Constellation licensees under its cloud-based distribution model. It has a partnership agreement with BGI Genomics Co., Ltd. to develop, manufacture, and commercialize NGS-based genetic testing assays for clinical and commercial use. The company has a collaboration with Diakonos Oncology Corp. to assess molecular response in patients with refractory melanoma. The company was formerly known as Gene Security Network, LLC and changed its name to Natera, Inc. in January 2012. Natera, Inc. was founded in 2003 and is headquartered in Austin, Texas.
Background via Yahoo Finance — informational, not part of the verdict.
⚪ NEUTRAL — No Edge
Signals are mixed with no clear edge in either direction. Stand aside and wait for one more confluence factor.
Scores: 2 bullish / 2 bearish
Weak — low conviction, small size or skip
SMC — Top Down
| Timeframe | Bias | Bars |
|---|---|---|
| 📅 Daily | RANGING | 62 |
| ⏰ 4H | BULLISH | 37 |
| 🕐 1H | RANGING | 98 |
| ⏱ 15-Min | RANGING | 130 |
| ⏲ 5-Min | BULLISH | 234 |
Momentum & Volume
Peer Movement
Peer movement computing — it will appear here on its own.
Insider Activity (90d)
CLUSTER SELL 0 buys · 120 sells
Recent: Rabinowitz Matthew sold 2275394 sh @ $267.99 (2026-08-03); Rabinowitz Matthew sold 2276125 sh @ $260.49 (2026-07-27); Rabinowitz Matthew sold 2327843 sh @ $219.36 (2026-06-12)
COT Positioning — E-MINI S&P 500 - CHICAGO MERCANTILE EXCHANGE
NEUTRAL report date 2026-09-01 · Asset managers net 934180 (-19048)
AI Summary
Plain-language summary of the evidence already on this page — the Sharia screen, structure, momentum, and order flow above. It explains the read; it doesn't make the call. Generated on demand (a live AI call), never run automatically.